AstraZeneca signed an AI-enabled target discovery deal with insitro, expanding the UK pharma’s use of machine-learning systems for drug discovery. The arrangement provides insitro with funding to run discovery work in multiple target areas, with the pharma set to take over later clinical, regulatory, and commercial responsibilities for resulting programs. The agreement highlights how large pharmaceutical companies are moving beyond internal AI pilots into structured, financially committed collaborations with specialized AI drug discovery firms. The partnership adds to insitro’s platform deal momentum and underscores continued investment in data-driven target identification, particularly for complex therapeutic areas such as liver and cardiovascular disease.